- Home
- ATYR
as 09-17-2025 4:00pm EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
| Founded: | 2005 | Country: | United States |
| Employees: | 59 | City: | SAN DIEGO |
| Market Cap: | 105.8M | IPO Year: | 2015 |
| Target Price: | $8.88 | AVG Volume (30 days): | 15.6M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $7.29 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | -33.43% |
| Revenue Growth (this year): | 420.85% | Revenue Growth (next year): | 1919.44% |
Latest aTyr Pharma Inc. Common Stock News
ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing
Insider Monkey
10 days ago
Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results
GlobeNewswire
12 days ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
3 months ago
Sector Update: Health Care Stocks Increase in Afternoon Trading
GlobeNewswire
3 months ago
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
Simply Wall St.
3 months ago
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing
GlobeNewswire
3 months ago
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Simply Wall St.
4 months ago
High Growth Tech Stocks in the US to Watch This May 2025
Insider Monkey
4 months ago
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential
Compare ATYR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.